Genentech Will Market OSI Cancer Drug In U.S. Under Three-Way Deal
Executive Summary
Genentech will market OSI Pharmaceuticals' anti-cancer drug OSI-774 in the U.S. under a three-way co-development and marketing deal between Genentech, Roche and OSI.
You may also be interested in...
Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said
Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said
Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa
Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa